Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NQO2 | P16083 | 1/20 | 0.53 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13649463 | 0.88 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HPGDL3MBTL1MEN1 | |
| SCHEMBL16594624 | 0.87 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2HPGDL3MBTL1MEN1 | |
| SCHEMBL2828273 | 0.87 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HPGDL3MBTL1MEN1 | |
| SCHEMBL2828269 | 0.87 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HPGDL3MBTL1MEN1 | |
| SCHEMBL951041 | 0.85 | PTPN1 (0.61) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL30791550 | 0.85 | PTPN1 (0.61) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL12862921 | 0.85 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2HPGDL3MBTL1MEN1 | |
| SCHEMBL29673865 | 0.83 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2HPGDL3MBTL1MEN1 | |
| SCHEMBL29673798 | 0.83 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2HPGDL3MBTL1MEN1 | |
| SCHEMBL27608578 | 0.83 | SMN1; SMN2 (0.59) | ALDH1A1SMN1; SMN2HPGDL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| WO-2009124962-A2 | SULFONAMIDES | MERCK SERONO S.A. (CH) | 2009-10-15 | — | — | WO | disclosed |
| EP-1243583-B1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | EISAI CO LTD (JP) | 2005-09-28 | — | — | EP | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-6787534-B2 | SUBSTITUTED QUINOLINE AND ISOQUINOLINE ANTIANGIOGENIC AGENTS; SULFONYLUREAS | EISAI CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1243583-A1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | Eisai Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-1224198-A1 | NUCLEOSIDE DERIVATIVES WITH PHOTOLABILE PROTECTING GROUPS | NIGU CHEMIE GMBH (DE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001032671-A1 | NUCLEOSIDE DERIVATIVES WITH PHOTOLABILE PROTECTING GROUPS | NIGU CHEMIE GMBH (DE) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | ALDH1A1 1256/4885SMN1; SMN2 2639/4885HPGD 4076/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | ALDH1A1 1256/4885SMN1; SMN2 2639/4885HPGD 4076/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | ALDH1A1 1266/4885SMN1; SMN2 2404/4885HPGD 4084/4885 |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | SLC5A2, SLC5A1, CBR3 | ALDH1A1 1018/4885SMN1; SMN2 1987/4885HPGD 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.